Press releases

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.